The earnings call reflects a positive outlook for Emergent, with significant financial improvements, increased guidance, and strong performance in international sales and NARCAN revenue. However, there were some declines in specific product sales and a decrease in revenue compared to the first half of 2024, which are being managed through strategic initiatives.

Company Guidance

During the second quarter of 2025, Emergent BioSolutions demonstrated significant financial and operational progress, surpassing internal guidance with revenues of $141 million, exceeding the guidance range of $95 million to $120 million. The company reported a year-to-date adjusted EBITDA of $106 million, prompting an upward revision of their 2025 adjusted EBITDA guidance to $175 million to $200 million. Liquidity increased by $297 million year-to-date, with total financial capacity of $367 million. The net leverage ratio improved from 9.9x to 1.9x debt-to-adjusted EBITDA. Notable achievements included a 50% rebound in NARCAN sales since the first quarter, strategic divestitures, and international medical countermeasure (MCM) sales accounting for 40% of revenues year-to-date. Emergent repurchased 1.1 million shares as part of a $50 million share repurchase program. For the full year 2025, the company projects total revenues of $765 million to $835 million and is focused on sustaining market leadership in biodefense and public health sectors.

Revenue and EBITDA Performance

Second quarter revenues reached $141 million, surpassing the guidance range of $95 million to $120 million by $21 million. Year-to-date adjusted EBITDA is $106 million, leading to an increased guidance range of $175 million to $200 million for 2025.

Financial Improvements

Liquidity has increased by $297 million year-to-date, with a current total financial capacity of $367 million. Net leverage has improved significantly to 1.9x debt-to-adjusted EBITDA from 9.9x in the second quarter of 2024.

International Sales and MCM Performance

International medical countermeasure (MCM) sales represent 40% of year-to-date revenues, and smallpox revenue saw material year-over-year improvement with a significant increase in international demand.

NARCAN Revenue Growth

NARCAN sales rebounded by 50% since the first quarter of 2025, following one-time events, and have gained market visibility, including participation in Amazon Prime Day and integration into Humana Medicare Part D.

Share Repurchase Program

A 12-month share repurchase program of $50 million has been implemented, with 1.1 million shares repurchased in the second quarter.

Emergent Biosolutions (EBS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EBS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.05 / -	1.37	―	―	―
Aug 06, 2025	2025 (Q2)	-0.41 / 0.16	-2.32	106.90% (+2.48)
May 07, 2025	2025 (Q1)	0.44 / 0.71	0.59	20.34% (+0.12)
Mar 03, 2025	2024 (Q4)	-0.50 / 0.05	-0.77	106.49% (+0.82)
Nov 06, 2024	2024 (Q3)	0.10 / 1.37	-0.54	353.70% (+1.91)
Aug 06, 2024	2024 (Q2)	-1.14 / -2.32	-1.06	-118.87% (-1.26)
May 01, 2024	2024 (Q1)	-0.98 / 0.59	-3.17	118.61% (+3.76)
Mar 06, 2024	2023 (Q4)	-0.19 / -0.77	-0.31	-148.39% (-0.46)
Nov 08, 2023	2023 (Q3)	-0.22 / -0.54	-1.27	57.48% (+0.73)
Aug 08, 2023	2023 (Q2)	-0.65 / -1.06	-0.86	-23.26% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EBS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$6.03	$8.24	+36.65%
May 07, 2025	$4.74	$6.36	+34.18%
Mar 03, 2025	$6.83	$6.39	-6.44%
Nov 06, 2024	$9.20	$11.00	+19.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Emergent Biosolutions (EBS) report earnings?

Emergent Biosolutions (EBS) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Emergent Biosolutions (EBS) earnings time?

Emergent Biosolutions (EBS) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EBS EPS forecast?

EBS EPS forecast for the fiscal quarter 2025 (Q3) is 0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing